A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

Clinical trial NCT06564844 · ACTIVE_NOT_RECRUITING

Trial details

NCT number

NCT06564844

Sponsor

AstraZeneca

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 3

Study type

INTERVENTIONAL

Start date

2024-10-15

Primary completion

2027-06-30

Enrollment

25

View on ClinicalTrials.gov